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BACKGROUND/INTRODUCTION
In December 2013, the U.S. Preventive Services Task Force issued a “B” rating for 
lung cancer screening with low-dose CT scan in adults ages 55 to 80 with a 30 
pack-year history and who continue to smoke or quit within the past 15 years.1 
Reimbursement guidelines from Medicare include documentation of shared decision-
making (SDM) with patients, though tools to facilitate decision support are limited.2 
Lung cancer screening has limited public awareness due to its relatively recent 
recommendation. 
OBJECTIVE
To create a lung cancer screening SDM tool and patient educational materials by a 
Patient and Stakeholder Advisory Committee (PASAC). 
METHODS
STUDY DESIGN
As part of the Reducing Cancer Disparities by Engaging Stakeholders (RCaDES) 
Initiative, an iterative process was applied to facilitate the creation of patient 
materials through regular convening of the PASAC and community testing. 
SETTING
Lehigh Valley Practice and Community- Based Research Network (LV-PBCRN), in 
collaboration with Thomas Jefferson University, prime contractor.
PARTICIPANTS
A PASAC comprised of patients, community and health network stakeholders 
including primary care and specialty clinicians and administrative representatives. 
METHODS
The PASAC reviewed evidence-based literature and screening pathways and 
developed a tool to facilitate SDM in the clinical encounter, as well as educational 
material to be distributed to patients who may be eligible for screening. Each 
committee member was asked to test materials with 10 other community members 




•  The PASAC chose the adoption of a standardized SDM tool (Option Grid™) and a 
de novo patient education tool for incorporation into the developing lung cancer 
screening program. 
•  The PASAC led the design, identification of core information, language and testing 
of the de novo product.
 •  The PASAC presented final materials to network leadership as part of a lung 
cancer screening program recommendation. 
CONCLUSION
•  Engaging patient and other stakeholders in the design of end-user educational 
materials is critical in creating culturally appropriate and tailored messaging materials. 
•  Utilizing a PASAC to create and test materials for patient and clinician end-users 
provides for low burden and exponential community feedback. 
NEXT STEPS
Materials will be piloted in the clinical setting as part of a comprehensive lung cancer 
screening and lung health program.
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CONSENSUSCURRICULUM MATERIAL DEVELOPMENT
•  Review of terms, pathways, 
coverage requirements,  
processes, literature
•  Review of current educational  
and evidence-based SDM tools
•  Brainstorming – Patient needs
•  Brainstorming – Provider/ 
Network Needs
•  Iterative mock-up process
•  Draft final products
•  Community testing and feedback
•  Iterative revision process
•  Consensus of materials
•  Presentation and recommendation 
to Leadership 




Screening using low dose CT No Screening
Who is it 
offered to?
High-risk smokers or ex-smokers:
•  Aged 55 to 80
•  Have smoked at least 1 pack a day for thirty years. 
•  No symptoms of lung cancer. 
Ex-smokers are offered screening if they have quit in the last 15 
years.
People who are not at high risk of 
lung cancer are not offered 
screening because there is no 
proven benefit to them.
How is lung 
cancer 
found?
Using low-dose CT: an x-ray offered once a year. 
This test takes a few minutes and needs no special preparation.
Without screening, lung cancer is 
usually found after symptoms are 
present or when other tests are done.
In these cases, lung cancer is more 
likely to be found at a later stage.
What are the 
benefits of 
screening?
Low-dose CT finds signs of possible lung cancer in roughly 1 in 
every 100 screened at a time when treatment has a better chance 
of success. 
65 in every 100 scans will not find any problems.
Does not apply
What are the 
harms or 
risks?
False alarms: Roughly 25 in every 100 people have small nodules 
found in their lungs. To make sure these nodules are not cancer, 
more tests are done, for up to 2 years.
Unnecessary treatment: Some suspicious nodules may be treated 
even though they may never cause problems.
Finding more problems: Low-dose CT sometimes reveals findings 
in other parts of the body. These may lead to more tests and 
possible treatment.
Radiation: There is a small radiation risk of CT scans, in this case it 
is similar to a dental x-ray
If are at risk and do not screen, you 
might worry that you have missed a 
chance to find the cancer early.
If cancer is found because of 
symptoms (like unexplained weight 
loss and coughing up blood) then the 
cancer is probably more advanced, 
and treatment will be more difficult.
What are the 
possible 
results?
25 people in every 100 screened will be told they have nodules, but 
few of these will be cancer. More tests will probably be done. 
Roughly 10 in every 100 people screened will be told about other 
problems, such as infections or lung damage from smoking.
Does not apply
